Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China

Fig. 3

Complete clinical response rate. The number of patients achieved complete clinical response after JAKi at the follow-up visit. Sixteen patients reached complete clinical response at 6 months. Thirty-seven patients reached response in 9 months, 42 patients in 12 months, and 44 patients in 18 months. In total, 44 refractory patients reached a response

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us